Patient-derived tumor organoids are revolutionizing drug development due to their clinical relevance. Nonetheless, their widespread adoption is constrained by the need for specialized expertise and primitive viability read-outs in high-throughput screenings. To address these challenges, we introduced DrugVision.AI, a university-operated automation platform enabling advanced organoid screening. Complementing this, our fully automated analysis platform, OrbitsTM, integrates novel, clinically relevant drug response metrics, providing intuitive visualizations and deeper insights into drug efficacy. Our innovations significantly lower barriers to organoid use in high-throughput applications, empowering both academic and industrial researchers.
Speaker: Christophe Deben, Center for Oncological Research (CORE), Universiteit Antwerpen